ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OASM Oasmia Pharmaceuticals AB

1.55
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Name Symbol Market Type
Oasmia Pharmaceuticals AB NASDAQ:OASM NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 1.55 1.01 2.14 0 01:00:00

Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeeme...

13/08/2019 11:03am

Edgar (US Regulatory)


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

  FORM 25

 

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-37604

 

 

 

OASMIA PHARMACEUTICAL AB

 

NASDAQ Capital Markets

 

(Exact name of Issuer as specified in its charter, and name of Exchange

where security is listed and/or registered)

 

 

 

Vallongatan 1

752 28 Uppsala, Sweden

+46 18 50 54 40

 (Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

 

American Depositary Shares, each representing three (3) Ordinary Shares, par value SEK 0.10 per share

Ordinary Shares, par value SEK 0.10 per share

(Description of class of securities)

 

 

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

¨ 17 CFR 240.12d2-2(a)(1)

 

¨ 17 CFR 240.12d2-2(a)(2)

 

¨ 17 CFR 240.12d2-2(a)(3)

 

¨ 17 CFR 240.12d2-2(a)(4)

 

¨ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

 

x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Oasmia Pharmaceutical AB certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

 

                     
August 12, 2019       By   /s/ Jörgen Olsson       Chairman of the Board
Date           Name       Title

 

 

***

 

 

 

1 Year Oasmia Pharmaceuticals AB Chart

1 Year Oasmia Pharmaceuticals AB Chart

1 Month Oasmia Pharmaceuticals AB Chart

1 Month Oasmia Pharmaceuticals AB Chart

Your Recent History

Delayed Upgrade Clock